Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J I Jorquera

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Clinical and Experimental Immunology|July 28, 2009
Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapyJ I Jorquera
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 31, 2008
Safety procedures of coagulation factorsJ I Jorquera
Sangre|May 24, 2000
[No ELISA detectable alterations in immunogenicity following dry-hear treatment (72 hours at 80 degrees C) of FANHDI]M I Bravo, M Massot, J I Jorquera
Pharmeuropa Scientific Notes|August 19, 2007
Effect of temperature on plasma freezing under industrial conditionsM I Bravo, S Grancha, J I Jorquera
Thrombosis and Haemostasis|June 28, 1983
Suppression of inhibitors in haemophilia with corticoids and factor VIIIJ A Aznar, J I Jorquera, A Peiro
Sangre|January 1, 1983
[Importance of corticoids in inhibitor suppression in hemophilia A, in addition to continuing treatment with factor VIII concentrate]J A Aznar, J I Jorquera, M L Marty
Thrombosis and Haemostasis|December 1, 1995
Laboratory diagnosis of APC-resistance in patients with lupus anticoagulantP Villa, J Aznar, J I Jorquera, et al.
Thrombosis and Haemostasis|April 30, 1984
The importance of corticoids added to continued treatment with Factor VIII concentrates in the suppression of inhibitors in haemophilia AJ A Aznar, J I Jorquera, A Peiró, et al.
Sangre|January 10, 1998
[Functionality of von Willebrand factor present in Fanhdi: adhesion to the vascular subendothelium in vitro]G Escolar, M Viñas, M Pino, et al.
Pharmeuropa Scientific Notes|August 19, 2007
Possible alternative to European Pharmacopoeia's method of analysis Test for Fc Function of Immunoglobulin (2.7.9) by using tetanus toxoid as antigenS Perez-del-Pulgar, M Lopez, M Gensana, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Immunology|July 28, 2009
Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapyJ I Jorquera
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 31, 2008
Safety procedures of coagulation factorsJ I Jorquera
Sangre|May 24, 2000
[No ELISA detectable alterations in immunogenicity following dry-hear treatment (72 hours at 80 degrees C) of FANHDI]M I Bravo, M Massot, J I Jorquera
Pharmeuropa Scientific Notes|August 19, 2007
Effect of temperature on plasma freezing under industrial conditionsM I Bravo, S Grancha, J I Jorquera
Thrombosis and Haemostasis|June 28, 1983
Suppression of inhibitors in haemophilia with corticoids and factor VIIIJ A Aznar, J I Jorquera, A Peiro
Sangre|January 1, 1983
[Importance of corticoids in inhibitor suppression in hemophilia A, in addition to continuing treatment with factor VIII concentrate]J A Aznar, J I Jorquera, M L Marty
Thrombosis and Haemostasis|December 1, 1995
Laboratory diagnosis of APC-resistance in patients with lupus anticoagulantP Villa, J Aznar, J I Jorquera, et al.
Thrombosis and Haemostasis|April 30, 1984
The importance of corticoids added to continued treatment with Factor VIII concentrates in the suppression of inhibitors in haemophilia AJ A Aznar, J I Jorquera, A Peiró, et al.
Sangre|January 10, 1998
[Functionality of von Willebrand factor present in Fanhdi: adhesion to the vascular subendothelium in vitro]G Escolar, M Viñas, M Pino, et al.
Pharmeuropa Scientific Notes|August 19, 2007
Possible alternative to European Pharmacopoeia's method of analysis Test for Fc Function of Immunoglobulin (2.7.9) by using tetanus toxoid as antigenS Perez-del-Pulgar, M Lopez, M Gensana, et al.
Pageof 4